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Abstract word count 257/250 
Abstract 
Background: Evidence from experimental studies suggests that atrazine and its analytes alter the timing 
of puberty in laboratory animals.  Such associations have not been investigated in humans.  
Objective: To determine the association between in utero exposure to atrazine analytes and earlier 
menarche attainment in a nested case-control study of the population-based Avon Longitudinal Study of 
Parents and Children. 
Methods: Cases were girls who reported menarche before 11.5 years while controls were girls who 
reported menarche at or after 11.5 years. Seven atrazine analyte concentrations were measured in 
maternal gestational urine samples (sample gestation week median (IQR): 12 (8-17)) for 174 cases and 
195 controls using high performance liquid chromatography-tandem mass spectrometry. We evaluated 
the study association using multivariate logistic regression, adjusting for potential confounders.  
Results: Diaminochlorotriazine (DACT) was the most frequently detected analyte (58% >limit of 
detection [LOD]) followed by desethyl atrazine (6%), desethyl atrazine mercapturate (3%), atrazine 
mercapturate (1%), hydroxyl atrazine (1%), atrazine (1%) and desisopropyl atrazine (0.5%). Because of 
low detection of other analytes, only DACT was included in the exposure–outcome analyses. The 
adjusted odds of early menarche (95% Confidence Interval) for girls with DACT exposures ≥median 
was 1.13 (0.82, 1.55) and exposure <median was 1.01 (0.73, 1.42) compared to girls with exposure 
<LOD (reference).  
Conclusions: This study is the first to examine the association between timing of menarche and atrazine 
analytes. We found a weak, non-significant association between in-utero exposure to atrazine metabolite 
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DACT and early menarche. Further exploration of the role of these exposures in female reproduction in 
other cohorts is needed.   
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Main text word count: 3349 
Introduction 
Atrazine is used in more than 70 countries worldwide; most frequently in the United States 
(U.S.), Brazil, Argentina, Mexico and China to control broadleaf and grassy weeds in agricultural crops, 
mainly corn (LeBaron et al. 2008; EPA 2012). Human exposure to atrazine can occur through several 
routes. Agricultural workers and those living near farms can be exposed to atrazine dispersed in air 
through spraying (ATSDR 2003). Exposure can also occur through contact with contaminated soils or 
ingestion of contaminated agricultural products (ATSDR 2003). Water run-off from crops and lawn 
applications can get into ground and surface waters and contaminate drinking water wells (Munger et al. 
1997). In water, atrazine breaks down to the following primary metabolites: desethyl atrazine (DEA), 
desisopropyl atrazine (DIA) and diaminochlorotriazine (DACT) (EPA 2012).  
In areas where atrazine is used, the general population can be exposed to atrazine analytes (i.e., 
atrazine parent compound or any of its metabolites) through contaminated drinking water (Munger et al. 
1997; Ocoa-Acuna et al. 1997; Villanueva et al. 2005). Developing fetuses and children can be exposed 
in utero or through breast milk (Balduini et al. 2003; Whyatt et al. 2003). Atrazine is broken down 
rapidly in the body and eliminated primarily in urine, within 24-48 hours (Catenacci et al. 1993). 
Although it does not bioaccumulate appreciably in humans, atrazine and its related compounds can 
persist in ground water, contaminating surface and drinking water sources (ATSDR 2003).  This 
persistent contamination of drinking water can result in continuous exposure in humans, and therefore 
can be of concern (UNEP and WHO 2012). 
In Great Britain, atrazine has mainly been used on maize and sweet corn crops (Fera Science Ltd 
2016). During the years 1990 to 1992, about 42,000 kg of atrazine was applied annually in Great Britain, 
with about 17,000 kg applied to about 10,000 hectares annually in the South Western region of England 
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(Fera Science Ltd 2016). The European Union (E.U.) banned the use of atrazine in 2003 because of its 
persistent contamination of drinking and ground water above the E.U. recommended limit of 0.1 parts 
per billion (ppb) (Sass and Colangelo 2006). However, several countries still use this herbicide including 
the US where it is a restricted use pesticide (ATSDR 2003). 
Animal studies have associated exposure to atrazine with hormone-related tumors and with 
alterations in reproductive functions suggesting potential endocrine disrupting effects from these 
exposures. In rats, atrazine induced an earlier onset (Cooper et al. 2007; Wetzel et al. 1994) and 
increased incidence of mammary gland tumors by disrupting the ovarian function (Cooper et al 2007). 
Atrazine also caused a disruption in estrus cycle in rats by impairing the ovulatory surge of luteinizing 
hormone (Wetzel et al. 1994). Lactational exposure to atrazine or DACT (Laws et al. 2000, Laws et al. 
2003) and prenatal exposure to atrazine (Davis et al. 2011) in female rats resulted in delayed puberty 
(vaginal opening) in the offspring. Further, DACT was demonstrated to be as potent as atrazine in 
delaying puberty (Laws et al. 2003). However, the doses associated with delayed puberty in these 
studies were high (50,000 – 200,000ppb daily). 
Several studies have reported a secular trend towards earlier onset of puberty among girls in 
Europe and the United States (Aksglaede et al. 2008; Euling et al. 2008; McDowell et al. 2007; Parent et 
al. 2003; Semiz et al. 2008) with some reporting earlier age at onset of menarche. (Mc Dowell et al. 
2007; Semiz et al. 2008)  Early puberty is a risk factor for childhood risky behaviors (e.g., smoking, 
alcohol consumption and drug abuse) and adult-onset diseases (e.g., breast and ovarian cancer) (Gail et 
al. 1989; Moorman et al. 2009; vanJaarsveld et al. 2007; Walvoord 2010). Epidemiologic studies of 
other endocrine disrupting chemicals (EDCs) suggest that in utero exposure to the estrogenic effect of 
EDCs is associated with early onset of puberty (Blanck et al. 2000; Vasiliu et al. 2004). Evidence from 
experimental studies suggests that atrazine analytes alter the timing of puberty in laboratory animals, 
however, such associations have not been investigated in humans.  This study uses a nested case-control 
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study design to measure atrazine analytes in maternal gestational urine as a proxy for in utero exposure 
of cases and controls to atrazine analytes, and examines the association with early menarche, as a marker 
of early puberty in girls. 
Methods 
Study population 
Pregnant women living in the Bristol area, in the south west of England, United Kingdom, with 
an expected date of delivery from 1st April, 1991 to 31st December, 1992, were recruited to participate 
in the Avon Longitudinal Study of Parents and Children (ALSPAC) (Fraser et al. 2013).  A total of 
14,775 live births were included in the ALSPAC cohort (Boyd et al. 2013). Details about recruitment 
and the study participants have already been published (Fraser et al. 2013; Boyd et al. 2013).  Beginning 
at the age of 8, a puberty questionnaire titled “Growing and Changing” was mailed to the participants 
each year until age 17 (except age 12) to collect information about the onset and progression of puberty 
in enrolled girls and boys (Rubin et al. 2009). For girls, onset of menarche information included the age 
and date of first menstrual period. The parents, the girls, or both completed the questionnaires (Rubin et 
al. 2009). The median age at onset of menarche (95% confidence interval [95% CI]) for girls who 
returned at least one puberty questionnaire (n= 3,938) was 12.87 years (10.82, 12.91) (Christensen et al. 
2010). The questionnaire is available on the study website at http://www.bristol.ac.uk/media-
library/sites/alspac/migrated/documents/ques-cb16a-mum-and-daughter-at-8.pdf. The website also 
contains detailed descriptions of available data accessible through a fully searchable online data 
dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/). 
The selection of cases and controls for the nested case-control study has been previously 
described (Christensen et al. 2011). In brief, 3,682 singleton girls returned at least 2 “Growing and 
Changing” questionnaires from ages 8 to 13 years. From this number 218 were identified as having 
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menarche before 11.5 years of age, and had one maternal gestational serum sample available for 
analysis. A subset of 174 cases also had one maternal gestational urine sample available for analysis. A 
random sample of 394 girls that had menarche at or after 11.5 years of age were selected as controls; 
230 of these had one maternal gestational serum sample and 195 also had one maternal gestational urine 
sample available for analysis. We included only the 174 cases and 195 controls with analyzable maternal 
gestational urine samples in this study. The urine samples were collected from mothers as part of routine 
antenatal care at random times during pregnancy (between 1st April 1991 and 31st December 1992), 
(Fraser et al. 2013; Boyd et al. 2013) therefore, stage of gestation and timing of urine collection may 
vary among mothers’ urine samples. Each urine sample was divided into small aliquots to maximize 
efficiency of the sample use, and banked at the University of Bristol (Boyd et al. 2013). The samples 
were stored at +4 or -20 degrees Celsius 0-6 days after initial collection then stored between -10 and -20 
degrees Celsius until analysis. Only one aliquot per mother was used for this study. The ALSPAC Law 
and Ethics Committee, the Local Research Ethics Committees, and the Centers for Disease Control and 
Prevention (CDC) Institutional Review Board assessed and approved human subject protection 
(Christensen et al. 2011). 
Exposure Assessment 
Banked urine samples from the University of Bristol were transferred to CDC’s Division of 
Laboratory Sciences within the National Center for Environmental Health in 2008, and analyzed during 
the same year. The following atrazine analytes were measured using on-line solid phase extraction-
isotope dilution-high performance liquid chromatography-tandem mass spectrometry: (Panuwet et al. 
2008, Panuwet et al. 2010) Atrazine, DACT, DEA, DIA, atrazine mercapturate, desethyl atrazine 
mercapturate, and hydroxyl atrazine. The limits of detection (LODs) were calculated as three times the 
standard deviation of the noise at zero concentration (Panuwet et al. 2008, Panuwet et al. 2010). An 
estimate of the noise was based on the variation in precision at concentrations close to the LODs 
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(Panuwet et al. 2008, Panuwet et al. 2010). Creatinine was measured for each urine sample on a Roche 
Hitachi Modular P Chemistry Analyzer (Hitachi, Pleasanton, CA, USA) using the Creatinine Plus 
Assay, as described in Roche’s Creatinine Plus Product Application # 04903773003.  
We calculated the median, and the 25th and 75th percentile only for analytes detected in more 
than 50% of sample measurements. Survival analyses methods are recommended when estimating 
distributions using data with values <LOD instead of methods that replace values <LOD with LOD/2 or 
LOD/√2 (Gillespie et al. 2010). Therefore, to calculate the median and percentiles, we used non-
parametric survival analysis methods using the LIFETEST procedure in SAS software version 9.3 (SAS 
Institute Inc., Cary, NC, USA) to account for the left censored values (<LOD) after transforming the 
data for left censoring.   
Exposure and early menarche analyses 
We classified exposure to analytes detected in more than 50% of sample measurements into the 
following 3 categories: <LOD, LOD to <median, and ≥median. We determined the median using the 
distribution of controls ≥LOD. We also dichotomized exposure as “Yes” (≥LOD) or “No” (<LOD). 
We selected the following covariates a priori from the literature, and evaluated them for their 
potential to confound the outcome–exposure association: Mother’s age at delivery (<20, 20–24, 25–29, 
30–39, or ≥40 years) (Adair 2001), mother’s pre-natal body mass index (BMI) (<18.5 [underweight], 
18.5–24.9 [normal], 25–29.9 [over-weight], or ≥30 [obese]) (Rubin et al. 2009), mother’s age at 
menarche (8–11, 12–14, or ≥15 years) (Rubin et al. 2009), mother’s education (Certificate of secondary 
education (CSE)/None, Vocational, O-level, A-level, or Degree) (Parent et al. 2009; Adair 2001), child’s 
birth weight (<2500g or ≥2500g) (Adair 2001; Ruder et al. 2010), child’s birth order (first born, second 
born, or third born or later) (Rubin et al. 2009), child’s BMI at age 7 (Rubin et al. 2009; Biro et al. 
2010), child’s duration of breast feeding (never, < 6 months , or ≥6 months) (Balduini et al. 2003), 
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trimester when gestational urine sample was collected (<12 weeks, 13–≤28 weeks, or ≥29 weeks) and 
month of urine sample collection (December–February, March–May, June–August, or September–
November), or (March–August or September–February) (Whyatt et al. 2003; Winchester et al. 2008). 
We used logistic regression methods in SAS 9.3 to evaluate the covariate–exposure and the 
covariate–outcome association. We considered covariates with a p-value (p) <0.25 (Mickey and 
Greenland 1989) for both associations to be potential confounders.  
We used multiple imputation methods in SAS 9.3 to impute values for missing covariate data 
(Liu and De 2015), and used these datasets with imputed covariate values to estimate the outcome–
exposure association. We used logistic regression to analyze the association between early menarche and 
in utero exposure to atrazine analytes, and then used the MIANALYZE procedure to combine the results 
from imputed datasets. We adjusted for urine creatinine by including it as a covariate in the multivariate 
model.  
Results 
Child’s birth order, child’s BMI at age 7, mother’s prenatal BMI and mother’s age at menarche 
significantly (p<0.05) differed between cases and controls (Table 1). Cases were more likely than 
controls to be first born children (61.5% vs. 52.1%), have a mother who was overweight (BMI 25–29.9) 
or obese (BMI>30) (17.7% and 10.4%, respectively vs. 8.3% and 3.9% of controls), or have a mother 
with onset of menarche between the ages 8–11 years (32.9% vs. 13.4% of controls) (Table 1). Cases had 
significantly higher BMIs at age 7 compared to controls (p <0.0001). Cases were also more likely to 
have a mother with either no education or a CSE (15.5% vs. 9.4% of controls) although this difference 
was not statistically significant. The median age at menarche for cases was 11 years compared to 12.8 
years for controls (Table 1). 
 10 
 
Atrazine was detected in only 0.8% of the study participants. DACT was the only analyte 
detected above the LOD in over 50% of the participants (58.3%) (Table 2). Other less frequently 
detected analytes were DEA (6.2%), desethyl atrazine mercapturate (3.3%), atrazine mercapturate (1.4 
%), hydroxyl atrazine (1%) and DIA (0.5%).  
Because of low detection of the other atrazine analytes, only DACT was included in the 
exposure–outcome analyses. Mothers prenatal BMI, child’s BMI at age 7, and child’s duration of 
breastfeeding were identified as potential confounders of the in utero exposure to DACT and early 
menarche association. Fifty two cases and 53 controls did not have the covariate data required for the 
adjusted analysis of DACT exposure and early menarche. Therefore, we used multiple imputation for 
the exposure–outcome association analyses.  
For the association between early menarche and dichotomized DACT exposure, the unadjusted 
odds ratio (95% CI) was 1.18 (0.78, 1.78), and the adjusted odds ratio (95% CI) was 1.12 (0.90, 1.40) 
(Table 3). For the association between early menarche and DACT exposure categories, the unadjusted 
odds ratio (95% CI) was 1.01 (0.61, 1.67) for the <median category and 1.34 (0.83, 2.18) for the 
≥median category compared to the reference (<LOD) (Table 3). The adjusted odds ratio (95% CI) was 
1.03 (0.74, 1.45) for the <median category and 1.13 (0.82, 1.55) for the ≥median category compared to 
the reference (Table 3). Even though the odds ratios were >1, none of the associations were statistically 
significant (the 95% CI included the null).  
When we excluded the cases and controls without covariate data from the analyses, the odds 
ratio for dichotomous exposure increased though the association remained non-significant (see 
supplemental material; see Table S1). However, for the categorical exposure, the unadjusted odds ratio 
(95% CI) was 1.11 (0.60, 2.06) for the <median category and 2.06 (1.16, 3.64) for the ≥median category 
compared to the reference (see supplemental material; see Table S1). The adjusted odds of early 
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menarche (95% CI) for girls with DACT exposures <median was 1.26 (0.65, 2.42) and for the ≥median 
was 1.86 (1.03, 3.38) compared to the reference (see supplemental material; see Table S1). The 
association was significant for both unadjusted and adjusted in utero exposure to DACT ≥median 
compared to the reference. 
Discussion 
To our knowledge, this study is the first to analyze the association between exposure to atrazine 
analytes and timing of menarche in humans. Our results suggest that earlier menarche is associated with 
in utero exposure to DACT, though the association is weak, the confidence intervals wide and include 
the null.  
The distribution profile of the analytes detected in the present study population suggests 
environmental exposure to atrazine as opposed to occupational exposures. Assessments of streams and 
ground water in the US showed that as atrazine persists in ground water, it breaks down to its degradates 
(e.g., DEA, DACT and DIA) such that the degradates are detected as frequently as, (Barbash et al. 1999) 
and at higher concentrations than the parent compound. (Gilliom et al. 2006) Barr et al. (2007), also 
reported that DACT is the analyte predominantly detected (77%) in populations exposed 
environmentally to atrazine (e.g., through contaminated water or food), followed distantly by DEA 
(15%), DIA (6%) and then atrazine mercapturate (2%). In our study, we detected DACT at 58%, 
followed by DEA (6%). We detected atrazine mercapturate and DIA in 1.4% and 0.5% of our study 
participants respectively. The environmental exposure profile we observed in ALSPAC participants is 
consistent with exposure to atrazine analytes through drinking water or food (Barr et al. 2007). The Barr 
et al. (2007) study had a small number of participants (N = 24), and even though DACT was the 
predominant atrazine analyte detected in the different exposure categories (environmental, occupational 
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and acute), the inter-person variations were about 30%. Further evaluation in larger studies is needed 
(Barr et al. 2007). 
In our study, a single sample of urine collected during pregnancy from each mother was used. 
Since atrazine has a short half-life of 8 hours with elimination from the body occurring in 24-48 hours, 
(Catenacci et al. 1993) atrazine analytes measured in the urine sample would most likely only describe 
exposure in the past 24–48 hours, and may not be an accurate representation of exposure throughout the 
pregnancy. However, the use of atrazine, e.g., agricultural applications, can lead to contaminated surface 
and ground water, which can result in persistent contamination of drinking water supplies (ATSDR 
2003; Munger 1997). If exposure to atrazine in this population occurred regularly through drinking 
water as suggested by the environmental exposure profile, the measurement of atrazine analytes in this 
study may be an adequate approximation of long-term exposure. This assumption does not take into 
account that some of the mothers may have other sources of drinking water, e.g., bottled water. Another 
factor that may not be taken into consideration is the water filtration systems at public drinking water 
supply systems or in the home. Although the use of only one urine sample may introduce error to the 
classification of exposure, this classification error is likely to be non-differential for cases and controls. 
The results of our study show that participants were exposed to several atrazine analytes. A 
recent study in France measured exposure to 8 atrazine analytes in urine samples from 579 pregnant 
women in the PELAGIE cohort, and examined the association with several adverse birth outcomes 
including fetal growth restriction and small head circumference (Chevrier 2011). DACT was detected in 
7% of the participants, DEA and DIA in 10%, and 4% of the participants respectively, and atrazine 
mercapturate in 4% (Chevrier 2011). In previous human exposure studies in the U.S., the analyte mainly 
measured has been atrazine mercapturate (Arcury 2007; Bakke 2009).  As atrazine is still in use in 
several countries including U.S., other metabolites including DACT, DEA and DIA need to be measured 
to better assess exposure. However, Barr et. al. (2007) state that “measuring atrazine compound or 
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atrazine mercapturate in urine is the unequivocal indication that a person was exposed to atrazine and 
not an environment degradate”.   
Our study results conflict with animal studies suggesting that atrazine and DACT may delay the 
onset of puberty by altering the hypothalamic-pituitary activity. In most of these studies the doses used 
to induce the observed outcomes are typically very high (50,000-200,000ppb), and do not compare to 
environmental levels that human populations are usually exposed to (median concentrations for DACT 
in our study are 0.27ng/mL (ppb) for cases and 0.24ppb for controls). Epidemiologic studies suggest that 
in utero exposure to the estrogenic effect of some EDCs is associated with early puberty (Blanck 2000; 
Vasiliu 2004). Animal studies suggest that atrazine does not bind to the estrogen receptor, and that the 
hypothalamic function is the main target of atrazine exposure (Cooper et al. 2007). A suggested 
endocrine disrupting mechanism of action associated with atrazine exposure is aromatase induction, 
which results in an increase in estrogen (Hayes et al. 2002; Sanderson et al. 2001). This increase may 
contribute to some estrogen-mediated toxicities observed in animal studies (e.g., induction and earlier 
onset of the incidence of mammary gland tumors, and lengthening of estrus cycle in rats) (Sanderson et 
al. 2001). More experimental studies conducted using doses of atrazine analytes at background levels, 
i.e., doses that populations are more likely to be exposed to, are needed to determine health outcomes, 
including onset of puberty, and mechanisms of action. 
A strength of this study is the ability to link to several demographic and health-related 
characteristics of the child and mother. A disadvantage of this study is use of only one urine sample 
during the pregnancy period. A second disadvantage is that age at menarche was self-reported by 
children or their parents, which could be subject to recall bias. Lastly, this study analyzed the association 
between in utero exposure to DACT and early menarche, not onset of puberty, which is marked by 
Tanner stage 2 breast development. 
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Conclusion 
Our results show a non-significant association between early menarche and in utero exposure to 
the atrazine analyte DACT in the ALSPAC cohort. Further exploration of the role of exposure to 
atrazine analytes in female reproduction in other large independent cohorts is needed. To 
comprehensively assess atrazine exposure in human populations, several analytes including DACT, 
DEA, and DIA, may need to be measured along with atrazine parent compound and atrazine 
mercapturate.  
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Tables  
Table 1 Study population characteristics 
 Cases (N=174) Controls (N=195)  
Characteristic N % N % p-valuea 
      
Mother’s ethnicity      0.88 
   White 167 98.2 189 98.4  
   Other Ethnicity 3 1.8 3 1.6  
   Missing 4  3   
      
Mother’s educationb     0.45 
   CSE/None 26 15.5 18 9.4  
   Vocational 12 7.1 14 7.3  
   O-Level 56 33.3 61 31.9  
   A-Level 48 28.6 64 33.5  
   Degree 26 15.5 34 17.8  
   Missing 6  14   
      
Mother’s  age at delivery (yrs)     0.36 
   <20 1 0.6 6 3.1  
   20-24 32 18.5 28 14.4  
   25-29 72 41.6 74 38  
   30-39 65 37.6 84 43.1  
   >40 3 1.7 3 1.5  
   Missing 1     
      
Mother’s prenatal BMI     0.004 
   <18.5 5 3.3 11 6.2  
   18.5-24.9 109 69.0 148 81.8  
   25-29.9 28 17.7 15 8.3  
   >30 16 10.4 7 3.9  
   Missing 16  14   
      
Mother’s age at menarche (yrs)     0.0003 
   8 – 11  50 32.9 22 13.4  
   12 – 14  92 60.5 126 76.8  
   ≥ 15  10 6.6 16 9.8  
   Missing 22  31   
      
Child’s birth order     0.03 
   First born 102 61.5 98 52.1  
   Second born 36 21.7 65 34.6  
   Third born or later 28 16.9 25 13.3  
   Missing 8  7   
      
 Median Quartile  Median Quartile  <0.0001 
Child’s BMI at age 7 17 15.7–18.9 15.9 15.2–16.8  
      
Child’s age at menarche (yrs) 11 10.7–11.3 12.8 12.3–13.3  
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Urine Sample gestation week 12 8– 17 13 9 – 18  0.23 
      
a Comparison of cases and controls using logistic regression 
b CSE = certificate of secondary education, O-level = ordinary level, A-level = advanced level 
 
Table 2 Gestational urine concentrations (ng/mL) 
 Total Casesc Controlsc p-value 
Analyte N (%) > 
LODa 
N (%) > 
LOD 
Median 
(quartiles) 
N (%) > 
LOD 
Median 
(quartiles) 
 
Diaminochlorotriazine 
(DACT) 
369 (58.3) 174 (60.3) 0.27 (0.16–
0.44) 
195 (56.4) 0.24 (0.16– 
0.41) 
0.31b 
Desethyl atrazine 
(DEA) 
369 (6.2) 174 (4.6)  195 (7.7)   
Desethyl atrazine 
mercapturate 
369 (3.3) 174 (2.3)  195 (4.1)   
Atrazine mercapturate 369 (1.4) 174 (0.6)  195 (2.1)   
Hydroxyl atrazine 369 (1.1) 174 (0.6)  195 (1.5)   
Atrazine 369 (0.8) 174 (0.6)  195 (1)   
Desisopropyl atrazine 
(DIA) 
369 (0.5) 174 (0.6)  195 (0.5)   
       
a The LODs were: atrazine, 0.05ng/mL; DACT, 0.19ng/mL; DEA, 0.10ng/mL; DIA, 0.12ng/mL; atrazine mercapturate, 
0.08ng/mL; desethyl atrazine mercapturate, 0.09ng/mL; and hydroxyl atrazine, 0.14ng/mL 
b Comparison between cases and controls using Wilcoxon Rank Sum test 
c Urine creatinine median (IQR) µg/g: Cases 81 (48-134) µg/g; Controls 80 (52-118) µg/g 
 
Table 3 Association between DACT gestational urine concentrations (ng/mL) and early menarche  
DACT n cases/controls Unadjusted OR (95%CI) Adjusted OR (95% CI) 
Dichotomous 
exposure 
   
<LOD 69/ 85 1 Reference 1 Reference 
≥LOD 105/ 110 1.18 (0.78 – 1.78)a 1.12 (0.90 – 1.40)a, c 
    
Categorical 
exposure  
   
< LODd 69/ 85 1 Reference 1 Reference 
LOD – < Mediand 45/ 55 1.01 (0.61–1.67) b 1.03 (0.74–1.45) b, c 
≥ Mediand 60/ 55 1.34 (0.83–2.18) b 1.13 (0.82–1.55) b, c 
a Odds of early menarche for DACT exposure ≥LOD compared to exposure <LOD 
b Odds of early menarche by DACT exposure category compared to reference (<LOD) 
c Adjusted for Mother’s pre-natal BMI, childhood BMI at age 7, duration of breastfeeding, and urine sample creatinine 
d DACT LOD = 0.19 ng/mL and Median of controls ≥LOD = 0.4 ng/mL 
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